Ocumension Therapeutics
歐康維視生物
(Incorporated in the Cayman Islands with limited liability)
(Stock code: 1477)

VOLUNTARY ANNOUNCEMENT
FIRST PATIENT ENROLLMENT COMPLETED IN THE PHASE III CLINICAL TRIAL OF OT-202

This announcement is made by Ocumension Therapeutics (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to keep the shareholders of the Company and potential investors informed of the latest business updates of the Group.

The board (the "**Board**") of directors of the Company is pleased to announce that the phase III clinical trial of OT-202 (Syk/VEGFR-2) for the treatment of dry eye disease ("**DED**") in the People's Republic of China (the "**PRC**") has enrolled its first patient. The successful enrollment of the first patient marks an important milestone in the clinical development of OT-202 in the PRC, and demonstrates the Group's commitment to advancing innovative therapies for DED patients.

OT-202 (Syk/VEGFR-2) is a first-in-class new drug self-developed by the Company for the treatment of moderate to severe dry eye. The mechanism of action of OT-202 is that the dual-targeted inhibitor of spleen tyrosine kinase (Syk) and vascular endothelial growth factor receptor-2 achieves a synergistic effect in the treatment of dry eye disease and inhibits the inflammatory response. OT-202 demonstrated a good safety and tolerability profile in healthy adult subjects in the phase I clinical trial successfully completed in February 2023. The phase II clinical trial of OT-202, which was launched in February 2023 and designed to be a randomized, double-masked, placebo-controlled clinical trial on the safety and efficacy of the drug, completed the enrollment of a total of 213 patients for the phase II clinical trial in China in November 2023. The phase II clinical trial results of OT-202 were published in the world's top ophthalmology journal *Ophthalmology*. In March 2024, the phase II clinical trial of OT-202 achieved its primary endpoints.

Cautionary Statement: The Company cannot guarantee that it will ultimately commercialize OT-202 (Syk/VEGFR-2) successfully. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Ocumension Therapeutics
Dr. Lian Yong CHEN
Chairman and Non-executive Director

Hong Kong, August 31, 2026

As of the date of this announcement, the Board comprises Mr. Ye LIU and Dr. Zhaopeng HU as executive Directors, Dr. Lian Yong CHEN, Mr. Yanling CAO and Dr. Qin XIE as non-executive Directors, and Ms. Beibei ZHUANG, Mr. Yiran HUANG and Mr. Zhenyu ZHANG as independent non-executive Directors.